Logo image of IMRX

IMMUNEERING CORP - CLASS A (IMRX) Stock Overview

NASDAQ:IMRX - US45254E1073 - Common Stock

5.92 USD
-0.03 (-0.5%)
Last: 8/26/2025, 6:43:09 PM
5.87 USD
-0.05 (-0.84%)
After Hours: 8/26/2025, 6:43:09 PM

IMRX Key Statistics, Chart & Performance

Key Statistics
52 Week High6.14
52 Week Low1.1
Market Cap215.01M
Shares36.32M
Float27.54M
Yearly DividendN/A
Dividend YieldN/A
EPS(TTM)-1.89
PEN/A
Fwd PEN/A
Earnings (Next)N/A N/A
IPO07-30 2021-07-30
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryBiotechnology


IMRX short term performance overview.The bars show the price performance of IMRX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 50 100 150 200 250

IMRX long term performance overview.The bars show the price performance of IMRX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 100 200 300 400

The current stock price of IMRX is 5.92 USD. In the past month the price increased by 60.87%. In the past year, price increased by 433.33%.

IMMUNEERING CORP - CLASS A / IMRX Daily stock chart

IMRX Competitors/Peers

The largest stocks on the US markets in the "Biotechnology" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
ABBV ABBVIE INC 19.68 368.08B
AMGN AMGEN INC 13.28 155.90B
GILD GILEAD SCIENCES INC 14.83 142.38B
VRTX VERTEX PHARMACEUTICALS INC 22.86 99.27B
REGN REGENERON PHARMACEUTICALS 12.88 62.29B
ALNY ALNYLAM PHARMACEUTICALS INC N/A 59.14B
ARGX ARGENX SE - ADR 76.39 43.34B
ONC BEONE MEDICINES LTD-ADR 6.24 36.72B
INSM INSMED INC N/A 27.94B
BNTX BIONTECH SE-ADR N/A 25.19B
NTRA NATERA INC N/A 22.74B
BIIB BIOGEN INC 8.54 20.04B

About IMRX

Company Profile

IMRX logo image Immuneering Corp. operates as a clinical-stage oncology company, which engages in developing medicines for cancer patients. The company is headquartered in Cambridge, Massachusetts and currently employs 66 full-time employees. The company went IPO on 2021-07-30. The firm is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, is in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the mitogen-activated protein kinase (MAPK) pathway. The Company’s second product candidate, IMM-6-415, is an oral, twice-daily deep cyclic inhibitor of mitogen-activated protein kinase kinase (MEK) in a Phase I/IIa trial in patients with advanced solid tumors harboring RAS or RAF mutations. Its pipeline also includes RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

Company Info

IMMUNEERING CORP - CLASS A

245 Main Street, Second Floor

Cambridge MASSACHUSETTS US

CEO: Benjamin J. Zeskind

Employees: 54

IMRX Company Website

IMRX Investor Relations

Phone: 16175008080

IMMUNEERING CORP - CLASS A / IMRX FAQ

What is the stock price of IMMUNEERING CORP - CLASS A today?

The current stock price of IMRX is 5.92 USD. The price decreased by -0.5% in the last trading session.


What is the ticker symbol for IMMUNEERING CORP - CLASS A stock?

The exchange symbol of IMMUNEERING CORP - CLASS A is IMRX and it is listed on the Nasdaq exchange.


On which exchange is IMRX stock listed?

IMRX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for IMMUNEERING CORP - CLASS A stock?

12 analysts have analysed IMRX and the average price target is 13.06 USD. This implies a price increase of 120.54% is expected in the next year compared to the current price of 5.92. Check the IMMUNEERING CORP - CLASS A stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is IMMUNEERING CORP - CLASS A worth?

IMMUNEERING CORP - CLASS A (IMRX) has a market capitalization of 215.01M USD. This makes IMRX a Micro Cap stock.


How many employees does IMMUNEERING CORP - CLASS A have?

IMMUNEERING CORP - CLASS A (IMRX) currently has 54 employees.


What are the support and resistance levels for IMMUNEERING CORP - CLASS A (IMRX) stock?

IMMUNEERING CORP - CLASS A (IMRX) has a support level at 3.79. Check the full technical report for a detailed analysis of IMRX support and resistance levels.


Should I buy IMMUNEERING CORP - CLASS A (IMRX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does IMMUNEERING CORP - CLASS A (IMRX) stock pay dividends?

IMRX does not pay a dividend.


What is the Price/Earnings (PE) ratio of IMMUNEERING CORP - CLASS A (IMRX)?

IMMUNEERING CORP - CLASS A (IMRX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.89).


What is the Short Interest ratio of IMMUNEERING CORP - CLASS A (IMRX) stock?

The outstanding short interest for IMMUNEERING CORP - CLASS A (IMRX) is 5.72% of its float. Check the ownership tab for more information on the IMRX short interest.


IMRX Technical Analysis

ChartMill assigns a technical rating of 10 / 10 to IMRX. When comparing the yearly performance of all stocks, IMRX is one of the better performing stocks in the market, outperforming 99.39% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

IMRX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to IMRX. IMRX has a great financial health rating, but its profitability evaluates not so good.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

IMRX Financial Highlights

Over the last trailing twelve months IMRX reported a non-GAAP Earnings per Share(EPS) of -1.89. The EPS increased by 1.05% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -121.73%
ROE -147.44%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%14.89%
Sales Q2Q%N/A
EPS 1Y (TTM)1.05%
Revenue 1Y (TTM)N/A

IMRX Forecast & Estimates

12 analysts have analysed IMRX and the average price target is 13.06 USD. This implies a price increase of 120.54% is expected in the next year compared to the current price of 5.92.


Analysts
Analysts81.67
Price Target13.06 (120.61%)
EPS Next Y17.43%
Revenue Next YearN/A

IMRX Ownership

Ownership
Inst Owners12.42%
Ins Owners16.69%
Short Float %5.72%
Short Ratio1.02